Lucemyra (Lofexidine HCl) Patent Expiration, LOE Window & CMS Spending

Lucemyra (Lofexidine HCl) by Biocorrx: Off-Patent Genericized (AB Competition), 3 AB generics, $23.2M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiocorrx
FDA Application & PathwayN209229 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$23.2M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$21.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.5% 2-yr change)